Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

150
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
150

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The immunogenicity database collaborative: a standardized, publicly available database for clinical immunogenicity observations and insights.

Frontiers in immunology·2026
Same authorSame journal

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same author

Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics.

Molecular therapy. Advances·2026
Same author

Weight Changes in Children and Adolescents with Epilepsy and Overweight/Obesity Treated with Zonisamide.

Childhood obesity (Print)·2026
Same author

Expansion trends and impacts of Phragmites australis on the Louisiana Gulf Coast.

Ecological applications : a publication of the Ecological Society of America·2026
Same author

Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm With Updated Criteria.

American journal of medical genetics. Part A·2026

相关实验视频

Updated: Jul 28, 2025

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.7K

关于生物治疗药物的免疫性风险评估工具的调查结果:对药物开发中的方法,应用和实用性的共识的洞察.

Jochem Gokemeijer1, Yi Wen2, Vibha Jawa3

  • 1Bristol Myers Squibb, 100 Binney Street, Cambridge, Massachusetts, 02143, USA. jochem.gokemeijer@bms.com.

The AAPS journal
|June 2, 2023
PubMed
概括

制药科学家使用计算和实验室方法来预测和评估早期发展中的药物免疫性风险. 这些策略为临床决策提供了信息,并简化了制造过程.

关键词:
这是一种生物治疗药物.统一化和化 统一化和化免疫性风险 免疫性风险在体外测定试验.在临床前的发展.参考材料是参考材料的参考材料.

更多相关视频

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.0K
Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens
09:08

Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens

Published on: September 12, 2016

8.8K

相关实验视频

Last Updated: Jul 28, 2025

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.7K
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.0K
Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens
09:08

Developing a Salivary Antibody Multiplex Immunoassay to Measure Human Exposure to Environmental Pathogens

Published on: September 12, 2016

8.8K

科学领域:

  • 制药科学 制药科学
  • 药物开发 药物开发
  • 免疫性评估的免疫性评估

背景情况:

  • 治疗产品免疫性 (TPI) 社区调查了制药科学家关于免疫性风险评估策略.
  • 该调查跨越了5年和两个阶段,收集了有关早期药物开发实践的数据.

研究的目的:

  • 了解在临床开发之前使用的当前免疫性风险评估策略.
  • 确定在风险评估中使用in silico和in vitro方法的趋势.
  • 探索这些评估如何影响药物开发能力,制造和临床战略.

主要方法:

  • 一个分为两个阶段的调查分发给制药科学家.
  • 调查使用in silico算法和in vitro测试格式的使用情况.
  • 收集有关应用免疫性风险评估结果的数据.

主要成果:

  • 广泛采用高吞吐率的in silico算法和基于人类免疫细胞的测试.
  • 使用蛋白质组学和专门测试,特别是当作用机制影响风险时.
  • 工具还提供了关于化学,制造和控制 (CMC) 风险的见解,有助于过程开发.

结论:

  • 免疫性风险评估是早期药物开发的组成部分,影响发现,CMC和非临床阶段.
  • 这些评估超出了早期发展范围,以指导临床策略和生物分析.
  • 这些发现突出了针对降低药物开发风险的综合战略的趋势.